Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease

Science Translational Medicine

Volumn 5, Issue 200, 2013, Pages

  Khurana, Surender ^a   Loving, Crystal L ^b   Manischewitz, Jody ^a   King, Lisa R ^a   Gauger, Phillip C ^c   Henningson, Jamie ^d   Vincent, Amy L ^b   Golding, Hana ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b NATIONAL ANIMAL DISEASE CENTER   (United States)

^c IOWA STATE UNIVERSITY   (United States)

^d Kansas State Veterinary Diagnostic Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HA2 ANTIBODY; HEMAGGLUTININ ANTIBODY; HYBRID PROTEIN; INFLUENZA VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS REACTION; DISEASE SEVERITY; EPITOPE MAPPING; HEMAGGLUTINATION INHIBITION; HEMOLYSIS; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INFLUENZA VACCINE ASSOCIATED ENHANCED RESPIRATORY DISEASE; INFLUENZA VIRUS A H1N2; MDCK CELL; MEMBRANE FUSION; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STRUCTURE; REVIEW; SEQUENCE ANALYSIS; SWINE; VIRUS FUSION; VIRUS PNEUMONIA;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CROSS REACTIONS; DISEASE MODELS, ANIMAL; DOGS; EPITOPES; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNE SERA; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H1N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MADIN DARBY CANINE KIDNEY CELLS; MOLECULAR SEQUENCE DATA; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; RESPIRATORY TRACT DISEASES; SUS SCROFA; VACCINATION; VIRUS INTERNALIZATION;

EID: 84883859603     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3006366     Document Type: Review

References (47)

1. H. W. Kim, J. A. Bellanti, J. O. Arrobio, J. Mills, C. D. Brandt, R. M. Chanock, R. H. Parrott, Respiratory syncytial virus neutralizing activity in nasal secretions following natural infection. Proc. Soc. Exp. Biol. Med. 131, 658-661 (1969).
2. F. P. Polack, M. N. Teng, P. L. Collins, G. A. Prince, M. Exner, H. Regele, D. D. Lirman, R. Rabold, S. J. Hoffman, C. L. Karp, S. R. Kleeberger, M. Wills-Karp, R. A. Karron, A role for immune complexes in enhanced respiratory syncytial virus disease. J. Exp. Med. 196, 859-865 (2002).
3. V. A. Fulginiti, J. J. Eller, A. W. Downie, C. H. Kempe, Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines. JAMA 202, 1075-1080 (1967).
4. A. L. Vincent, S. L. Swenson, K. M. Lager, P. C. Gauger, C. Loiacono, Y. Zhang, Characterization of an influenza A virus isolated from pigs during an outbreak of respiratory disease in swine and people during a county fair in the United States. Vet. Microbiol. 137, 51-59 (2009).
5. A. L. Vincent, K. M. Lager, B. H. Janke, M. R. Gramer, J. A. Richt, Failure of protection and enhanced pneumonia with a US H1N2 swine influenza virus in pigs vaccinated with an inactivated classical swine H1N1 vaccine. Vet. Microbiol. 126, 310-323 (2008).
6. P. C. Gauger, A. L. Vincent, C. L. Loving, K. M. Lager, B. H. Janke, M. E. Kehrli Jr., J. A. Roth, Enhanced pneumonia and disease in pigs vaccinated with an inactivated human-like (d-cluster) H1N2 vaccine and challenged with pandemic 2009 H1N1 influenza virus. Vaccine 29, 2712-2719 (2011).
7. P. C. Gauger, A. L. Vincent, C. L. Loving, J. N. Henningson, K. M. Lager, B. H. Janke, M. E. Kehrli Jr., J. A. Roth, Kinetics of lung lesion development and pro-inflammatory cytokine response in pigs with vaccine-associated enhanced respiratory disease induced by challenge with pandemic (2009) A/H1N1 influenza virus. Vet. Pathol. 49, 900-912 (2012).
8. A. J. Caton, G. G. Brownlee, J. W. Yewdell, W. Gerhard, The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 31, 417-427 (1982).
9. S. Khurana, C. Larkin, S. Verma, M. B. Joshi, J. Fontana, A. C. Steven, L. R. King, J. Manischewitz, W. McCormick, R. K. Gupta, H. Golding, Recombinant HA1 produced in E. coli forms functional oligomers and generates strain-specific SRID potency antibodies for pandemic influenza vaccines. Vaccine 29, 5657-5665 (2011).
10. S. Khurana, N. Verma, J. W. Yewdell, A. K. Hilbert, F. Castellino, M. Lattanzi, G. Del Giudice, R. Rappuoli, H. Golding, MF59 adjuvant enhances diversity and affinity of antibodymediated immune response to pandemic influenza vaccines. Sci. Transl. Med. 3, 85ra48 (2011).
11. S. Khurana, N. Verma, K. R. Talaat, R. A. Karron, H. Golding, Immune response following H1N1pdm09 vaccination: Differences in antibody repertoire and avidity in young adults and elderly populations stratified by age and gender. J. Infect. Dis. 205, 610-620 (2012).
12. N. Verma, M. Dimitrova, D. M. Carter, C. J. Crevar, T. M. Ross, H. Golding, S. Khurana, Influenza virus H1N1pdm09 infections in the young and old: Evidence of greater antibody diversity and affinity for the hemagglutinin globular head domain (HA1 domain) in the elderly than in young adults and children. J. Virol. 86, 5515-5522 (2012).
13. P. A. Bullough, F. M. Hughson, J. J. Skehel, D. C. Wiley, Structure of influenza haemagglutinin at the pH of membrane fusion. Nature 371, 37-43 (1994).
14. L. Zhu, Y. Li, S. Li, H. Li, Z. Qiu, C. Lee, H. Lu, X. Lin, R. Zhao, L. Chen, J. Z. Wu, G. Tang, W. Yang, Inhibition of influenza A virus (H1N1) fusion by benzenesulfonamide derivatives targeting viral hemagglutinin. PLoS One 6, e29120 (2012).
15. W. Hunziker, I. Mellman, Expression of macrophage-lymphocyte Fc receptors in Madin-Darby canine kidney cells: Polarity and transcytosis differ for isoforms with or without coated pit localization domains. J. Cell Biol. 109, 3291-3302 (1989).
16. J. W. Yewdell, W. Gerhard, T. Bachi, Monoclonal anti-hemagglutinin antibodies detect irreversible antigenic alterations that coincide with the acid activation of influenza virus A/PR/834-mediated hemolysis. J. Virol. 48, 239-248 (1983).
17. Y. Ghendon, S. Markushin, H. Heider, S. Melnikov, V. Lotte, Haemagglutinin of influenza A virus is a target for the antiviral effect of Norakin. J. Gen. Virol. 67 (Pt. 6), 1115-1122 (1986).
18. U. Kumlin, S. Olofsson, K. Dimock, N. Arnberg, Sialic acid tissue distribution and influenza virus tropism. Influenza Other Respi. Viruses 2, 147-154 (2008).
19. S. G. Van Poucke, J. M. Nicholls, H. J. Nauwynck, K. Van Reeth, Replication of avian, human and swine influenza viruses in porcine respiratory explants and association with sialic acid distribution. Virol. J. 7, 38 (2010).
20. R. K. Nelli, S. V. Kuchipudi, G. A. White, B. B. Perez, S. P. Dunham, K. C. Chang, Comparative distribution of human and avian type sialic acid influenza receptors in the pig. BMC Vet. Res. 6, 4 (2010).
21. R. A. Medina, A. García-Sastre, Influenza A viruses: New research developments. Nat. Rev. Microbiol. 9, 590-603 (2011).
22. R. G. Webster, W. J. Bean, O. T. Gorman, T. M. Chambers, Y. Kawaoka, Evolution and ecology of influenza A viruses. Microbiol. Rev. 56, 152-179 (1992).
23. H. L. Forrest, R. G. Webster, Perspectives on influenza evolution and the role of research. Anim. Health Res. Rev. 11, 3-18 (2010).
24. L. Fairbairn, R. Kapetanovic, D. P. Sester, D. A. Hume, The mononuclear phagocyte system of the pig as a model for understanding human innate immunity and disease. J. Leukoc. Biol. 89, 855-871 (2011).
25. M. M. Swindle, A. Makin, A. J. Herron, F. J. Clubb Jr., K. S. Frazier, Swine asmodels in biomedical research and toxicology testing. Vet. Pathol. 49, 344-356 (2012).
26. F. Meurens, A. Summerfield, H. Nauwynck, L. Saif, V. Gerdts, The pig: A model for human infectious diseases. Trends Microbiol. 20, 50-57 (2012).
27. D. R. Braucher, J. N. Henningson, C. L. Loving, A. L. Vincent, E. Kim, J. Steitz, A. A. Gambotto, M. E. Kehrli Jr., Intranasal vaccination with replication-defective adenovirus type 5 encoding influenza virus hemagglutinin elicits protective immunity to homologous challenge and partial protection to heterologous challenge in pigs. Clin. Vaccine Immunol. 19, 1722-1729 (2012).
28. M. Throsby, E. van den Brink, M. Jongeneelen, L. L. Poon, P. Alard, L. Cornelissen, A. Bakker, F. Cox, E. van Deventer, Y. Guan, J. Cinatl, J. ter Meulen, I. Lasters, R. Carsetti, M. Peiris, J. de Kruif, J. Goudsmit, Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 3, e3942 (2008).
29. J. Sui, W. C. Hwang, S. Perez, G. Wei, D. Aird, L. M. Chen, E. Santelli, B. Stec, G. Cadwell, M. Ali, H. Wan, A. Murakami, A. Yammanuru, T. Han, N. J. Cox, L. A. Bankston, R. O. Donis, R. C. Liddington, W. A. Marasco, Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16, 265-273 (2009).
30. D. C. Ekiert, G. Bhabha, M. A. Elsliger, R. H. Friesen, M. Jongeneelen, M. Throsby, J. Goudsmit, I. A. Wilson, Antibody recognition of a highly conserved influenza virus epitope. Science 324, 246-251 (2009).
31. D. Corti, F. Sallusto, A. Lanzavecchia, High throughput cellular screens to interrogate the human T and B cell repertoires. Curr. Opin. Immunol. 23, 430-435 (2011).
32. G. S. Tan, F. Krammer, D. Eggink, A. Kongchanagul, T. M. Moran, P. Palese, A pan-H1 antihemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo. J. Virol. 86, 6179-6188 (2012).
33. S. Khurana, A. L. Suguitan Jr., Y. Rivera, C. P. Simmons, A. Lanzavecchia, F. Sallusto, J. Manischewitz, L. R. King, K. Subbarao, H. Golding, Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets. PLoS Med. 6, e1000049 (2009).
34. S. Khurana, W. Chearwae, F. Castellino, J. Manischewitz, L. R. King, A. Honorkiewicz, M. T. Rock, K. M. Edwards, G. Del Giudice, R. Rappuoli, H. Golding, Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci. Transl. Med. 2, 15ra5 (2010).
35. A. C. Monsalvo, J. P. Batalle, M. F. Lopez, J. C. Krause, J. Klemenc, J. Z. Hernandez, B. Maskin, J. Bugna, C. Rubinstein, L. Aguilar, L. Dalurzo, R. Libster, V. Savy, E. Baumeister, G. Cabral, J. Font, L. Solari, K. P. Weller, J. Johnson, M. Echavarria, K. M. Edwards, J. D. Chappell, J. E. Crowe Jr., J. V. Williams, G. A. Melendi, F. P. Polack, Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. Nat. Med. 17, 195-199 (2011).
36. K. K. To, A. J. Zhang, I. F. Hung, T. Xu, W. C. Ip, R. T. Wong, J. C. Ng, J. F. Chan, K. H. Chan, K. Y. Yuen, High titer and avidity of nonneutralizing antibodies against influenza vaccine antigen are associated with severe influenza. Clin. Vaccine Immunol. 19, 1012-1018 (2012).
37. K. K. To, K. H. Chan, I. W. Li, T. Y. Tsang, H. Tse, J. F. Chan, I. F. Hung, S. T. Lai, C. W. Leung, Y. W. Kwan, Y. L. Lau, T. K. Ng, V. C. Cheng, J. S. Peiris, K. Y. Yuen, Viral load in patients infected with pandemic H1N1 2009 influenza A virus. J. Med. Virol. 82, 1-7 (2010).
38. R. Platt, A. L. Vincent, P. C. Gauger, C. L. Loving, E. L. Zanella, K. M. Lager, M. E. Kehrli Jr., K. Kimura, J. A. Roth, Comparison of humoral and cellular immune responses to inactivated swine influenza virus vaccine in weaned pigs. Vet. Immunol. Immunopathol. 142, 252-257 (2011).
39. J. Loebbermann, L. Durant, H. Thornton, C. Johansson, P. J. Openshaw, Defective immunoregulation in RSV vaccine-augmented viral lung disease restored by selective chemoattraction of regulatory T cells. Proc. Natl. Acad. Sci. U.S.A. 110, 2987-2992 (2013).
40. R. Rudraraju, B. G. Jones, R. Sealy, S. L. Surman, J. L. Hurwitz, Respiratory syncytial virus: Current progress in vaccine development. Viruses 5, 577-594 (2013).
41. B. R. Murphy, G. A. Prince, E. E. Walsh, H. W. Kim, R. H. Parrott, V. G. Hemming, W. J. Rodriguez, R. M. Chanock, Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J. Clin. Microbiol. 24, 197-202 (1986).
42. B. R. Murphy, E. E. Walsh, Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J. Clin. Microbiol. 26, 1595-1597 (1988).
43. M. F. Delgado, S. Coviello, A. C. Monsalvo, G. A. Melendi, J. Z. Hernandez, J. P. Batalle, L. Diaz, A. Trento, H. Y. Chang, W. Mitzner, J. Ravetch, J. A. Melero, P. M. Irusta, F. P. Polack, Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat. Med. 15, 34-41 (2009).
44. C. A. Shaw, G. Otten, A. Wack, G. A. Palmer, C. W. Mandl, M. L. Mbow, N. Valiante, P. R. Dormitzer, Antibody affinity maturation and respiratory syncytial virus disease. Nat. Med. 15, 725 (2009).
45. P. G. Halbur, P. S. Paul, M. L. Frey, J. Landgraf, K. Eernisse, X. J. Meng, M. A. Lum, J. J. Andrews, J. A. Rathje, Comparison of the pathogenicity of two US porcine reproductive and respiratory syndrome virus isolates with that of the Lelystad virus. Vet. Pathol. 32, 648-660 (1995).
46. K. Tamura, D. Peterson, N. Peterson, G. Stecher, M. Nei, S. Kumar, MEGA5: Molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol. Biol. Evol. 28, 2731-2739 (2011).
47. S. Khurana, C. L. Loving, J. Manischewitz, L. R. King, P. C. Gauger, J. Henningson, A. L. Vincent, H. Golding, Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease. Sci. Transl. Med. 5, 200ra114 (2013).